A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507291-52-00

Acronym

IELSG38

Enrollment

106

Registered

2024-10-01

Start date

2014-03-24

Completion date

Unknown

Last updated

2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extranodal Marginal Zone Lymphoma

Brief summary

Complete Remission rate at the end of induction phase (6 months)

Detailed description

Response Rate (Complete and partial remission rates) at the end of induction phase ( 6 months from study entry), Progression Free Survival, Event-free-survival (EFS) at 5 years, Overall survival, Response duration, Acute and long-term toxicity

Interventions

DRUGMabThera 500 mg concentrate for solution for infusion

DRUGMabThera 1400 mg solution for subcutaneous injection

DRUGCHLORAMBUCIL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Complete Remission rate at the end of induction phase (6 months)	—

Secondary

Measure	Time frame
Response Rate (Complete and partial remission rates) at the end of induction phase ( 6 months from study entry), Progression Free Survival, Event-free-survival (EFS) at 5 years, Overall survival, Response duration, Acute and long-term toxicity	—

Countries

France, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026